GlassScriptPhysician profile
Therese H Roche
NPI 1740460286
$1,240.63
in general payments reported to CMS, 2019-2025
19 companies · $1,241 in 2025
The $1,241 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.64 |
| Education | $191.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $237.95 | 2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $164.95 | 2025 | Calquence, Enhertu, Imfinzi |
| Adc Therapeutics America, INC. | $123.74 | 2025 | |
| Exact Sciences Corporation | $107.10 | 2025 | The Cologuard Plus Collection Kit |
| Vertex Pharmaceuticals Incorporated | $103.12 | 2025 | |
| Daiichi Sankyo INC. | $75.92 | 2025 | Datroway |
| Novartis Pharmaceuticals Corporation | $74.09 | 2025 | |
| Incyte Corporation | $45.92 | 2025 | Monjuvi, Zynyz, Jakafi |
| Janssen Biotech, INC. | $44.89 | 2025 | Balversa, Erleada |
| Genentech USA, INC. | $39.78 | 2025 | Itovebi, Venclexta |
| Lilly USA, LLC | $32.40 | 2025 | Verzenio |
| Astellas Pharma US INC | $28.18 | 2025 | Vyloy |
| Abbvie INC. | $26.66 | 2025 | |
| Caris Mpi, INC. | $26.50 | 2025 | Mi Cancer Seek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.53 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $24.23 | 2025 | |
| Pharmaand Gmbh | $23.50 | 2025 | Rubraca |
| Stemline Therapeutics INC. | $22.59 | 2025 | Orserdu |
| Genzyme Corporation | $14.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Therese Roche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.